NMN vs NR Supplements Compared: What the Evidence Actually Shows in 2026
A candid breakdown of top NAD+ booster brands reveals strong biomarker data but slim evidence for real longevity outcomes.
86 artigos
A candid breakdown of top NAD+ booster brands reveals strong biomarker data but slim evidence for real longevity outcomes.
A new framework redefines age-related insulin resistance as a systemic collapse of metabolic resilience spanning muscle, fat, brain, and more.
A major review in Nature Medicine explores how CAR cell therapies may achieve deep immune 'reset' in autoimmune diseases by depleting pathogenic B cells.
Aging disrupts gut microbiota and mTOR signaling, crippling vaccine responses — but targeted interventions may reverse this.
A 2026 comparative review of leading NAD+ supplements reveals NR has stronger human data, while NMN marketing often outpaces clinical proof.
A Circulation review from Harvard proposes the 'target trial framework' to improve how observational data is used to assess cardiovascular device safety and effectiveness.
Age-related shifts in intestinal T cell populations may silently erode gut barrier function, accelerating the chronic inflammation that drives aging diseases.
Expert reviews compare NMN and NR head-to-head. NMN edges out for muscle and sleep benefits; NR leads for neuroprotection.
A Cochrane review of 37 RCTs finds obesity drugs modestly reduce weight in adolescents, but evidence quality is low and long-term data are absent.
A new review reframes how myeloid cells fuel or fight tumors, pointing to plasticity — not just cell diversity — as the core therapeutic target.
The American Heart Association's 2026 update outlines evidence-based strategies to slow disease progression and protect grafts after CABG.
A head-to-head review of 10 CGM devices for healthy adults, weighing real-world accuracy data against limited longevity evidence.